Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06813924 · ClinicalTrials.gov registry record · Phase 1
A Research Study of the Effect of Etavopivat on Other Drugs in Healthy Participants
A Phase 1 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 1
- Development phase
- 37
- Enrollment target
NCT06813924 is a Phase 1 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 37 participants.
The verdict
NCT06813924, a Phase 1 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 37 participants
- Enrollment target
Study Summary
The study aims to test if a new medicine called etavopivat potentially affects other medicines in healthy participants. The purpose of the study is to investigate whether the use of etavopivat affects the breakdown and metabolism of commonly used medicines in the body. During the study, participants will receive etavopivat and five different medicines that are already approved and available on the market, and which can be prescribed by doctors. These marketed medicines are called substrate drugs and they are: digoxin, pitavastatin, metformin, midazolam, and rosuvastatin. During a period of the study, participants will take 2 tablets of etavopivat daily for 10 consecutive days. The study will last for about 34 to 64 days.
Interventions
- DRUG Midazolam
- DRUG Metformin
- DRUG Etavopivat
- DRUG Digoxin
- DRUG Pitavastatin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2025-02-06 |
| Est. Completion | 2025-05-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06813924
The ClinicalTrials.gov registry entry for NCT06813924 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Midazolam is the first listed.
NCT06813924 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06813924 about?
NCT06813924 is a clinical study titled "A Research Study of the Effect of Etavopivat on Other Drugs in Healthy Participants". The study aims to test if a new medicine called etavopivat potentially affects other medicines in healthy participants. The purpose of the study is to investigate whether the use of etavopivat affects the breakdown and metabolism of commonly used medicines in the body. During the study, participants...
What is the current status of trial NCT06813924?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 37 participants. The study started on 2025-02-06. Estimated completion is 2025-05-27.
What interventions are being tested in trial NCT06813924?
The interventions under investigation include: Midazolam (DRUG), Metformin (DRUG), Etavopivat (DRUG), Digoxin (DRUG), Pitavastatin (DRUG).
Who is sponsoring clinical trial NCT06813924?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.